Stay updated with breaking news from Sheldon Koenig. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
NILEMDO? (bempedoic acid), a first-in-class, oral treatment and NUSTENDI? (bempedoic acid ezetimibe fixed-dose combination) receive label update approval from the European Commission as treatments
– Q1 Total Revenue Grew 467% Y/Y to $137.7 Million, Reflecting Strong Growth Globally – – Q1 U.S. Net Product Revenue Grew 46% Y/Y to $24.8 Million – – Q1 Retail Prescription Equivalents...
The FDA has expanded the approval of Nexletol and Nexlizet to prevent myocardial infarction and coronary revascularization in both primary and secondary prevention patients.
ANN ARBOR, Mich., April 01, 2024 -- Esperion today announced that Sheldon Koenig, President and CEO, will ring the Nasdaq Stock Market opening bell at 9:30 a.m. ET today, April 1, 2024, to...
Approvals based on positive CLEAR Outcomes data and reflect a highly differentiated product profile